The Tissue Procurement Core in conjunction with the Molecular Core Facility is housed in a 3,000 sq. foot laboratory facility located in Barnes- Jewish Hospital North Kinghighway building. The Core maintains equipment for tissue processing, sample storage, and database maintenance. This includes specimen freezing baths, two ultralow mechanical freezers, two microtome, equipment and supplies for standard histological staining, and a standard light microscope. The Core is also equipped with basic instruments for the preparation and electrophoretic analysis of nucleic acids. Two Pentium-based computers (one workstation and one laptop unit) are used for data entry and retrieval. In addition, the Core maintains and operates a pixcell II laser-capture microdissection microscope that is available for investigator use. The Core is directed by Dr. Mark A. Watson, a board certified clinical pathologists and an NCI-funded investigator with research interests in gene expression profiling, molecular cancer diagnostics, and the molecular biology of breast cancer.. As director of the Core, he is responsible for supervising most aspects of its day-to-day operation including: supervision of research assistants in tissue and macromolecule processing, quality control of molecular preparations, developing and updating procedures and laboratory equipment for macromolecular processing of specimens, administering investigator requests for patient specimens, administering investigators requests for patient specimens, and designing, implementing, and updating the Core's specimen database and web site. The Core is staffed by 2.5 full time employee equivalents. Victoria Holtschlag, B.S., administration of the laboratory. This includes accepting requests from investigators, preparing molecular and histological specimens for studies (DNA, RNA, frozen sections, paraffin embedded sections), updating protocols, ordering, billing, and laboratory maintenance. In consultation with the director(s), Ms. Holtschlag organizes projects and performs quality assurance (histological and molecular) of specimens. She also assists investigators in the training and use of the Laser Capture Microdissection instrument. Ms. Holtschlag is a certified medical technologist with over twenty years of experience in administering and supervising clinical laboratories. In addition to specimen procurement for specific studies, the Core maintains an archive of several thousand frozen tissue specimens (non- malignant and tumor tissue) collected from routine surgeries. This includes over 1,000 gastrointestinal tumor specimens. Pathology and limited demographic data is available for all specimens. Many tissues are collected as non-anonymized specimens from patients who have signed full informed consent for the Core to obtain follow-up clinical information based on maintained patient identifiers. Investigators may received coded clinical and follow-up data on """"""""as-needed"""""""" basis. For almost all requests patient specimens are processed to DNA, RNA, or cut as histological sections. A representative section of the specimen is also sectioned and stained to confirm pathological diagnosis and are qualitatively assess the tissues for percent necrosis and tumor cell content. Isolated nucleic acids are qualitatively assessed by agarose gel electrophoresis and quantified by UV absorbence. This quality controlled material is then distributed to the requesting investigator where it can be immediately used for biochemical or genetic analysis.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01GM063340-01
Application #
6495939
Study Section
Special Emphasis Panel (ZRG1)
Project Start
2001-08-01
Project End
2005-07-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Marsh, Sharon; King, Cristi R; Van Booven, Derek J et al. (2015) Pharmacogenomic assessment of Mexican and Peruvian populations. Pharmacogenomics 16:441-8
Patel, Jai N; Jiang, Chen; Hertz, Daniel L et al. (2015) Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 121:1025-31
Hariani, Gunjan D; Lam, Ernest T; Lam, Ernest J et al. (2014) Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics. BMC Res Notes 7:360
McWhinney-Glass, Sarah; Winham, Stacey J; Hertz, Daniel L et al. (2013) Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res 19:5769-76
Trammel, Morgan; Roederer, Mary; Patel, Jai et al. (2013) Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists? Curr Oncol Rep 15:276-85
Motsinger-Reif, Alison A; Jorgenson, Eric; Relling, Mary V et al. (2013) Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics 23:383-94
Brown, Kevin C; Hosseinipour, Mina C; Hoskins, Janelle M et al. (2012) Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. Pharmacogenomics 13:113-21
Crowley, James J; Kim, Yunjung; Szatkiewicz, Jin Peng et al. (2012) Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. Mamm Genome 23:322-35
He, Y J; McLeod, H L (2012) Ready when you are: easing into preemptive pharmacogenetics. Clin Pharmacol Ther 92:412-4
Hoskins, Janelle M; Ong, Pei-Shi; Keku, Temitope O et al. (2012) Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcome. PLoS One 7:e41954

Showing the most recent 10 out of 181 publications